International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

A Phase II Trial of Autologous Stem Cell Transplantation Followed by Mini-Allogeneic Stem Cell Transplantation for the Treatment of Multiple Myeloma: An Analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97

(2009) David H. Vesole et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

(2009) J. Koreth et al.   BLOOD

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

(2009) S. Kumar et al.   BLOOD

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

(2009) H. M. Lokhorst et al.   BLOOD

CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT

(2009) M Kapp et al.   BONE MARROW TRANSPLANTATION

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

(2009) M Lioznov et al.   BONE MARROW TRANSPLANTATION

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation

(2009) Nicolaus Kröger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rapid Identification of Clinical Relevant Minor Histocompatibility Antigens via Genome-Wide Zygosity-Genotype Correlation Analysis

(2009) R. M. Spaapen et al.   CLINICAL CANCER RESEARCH

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma

(2009) Nicolaus Kröger et al.   EXPERIMENTAL HEMATOLOGY

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population

(2009) B. Blanco et al.   HAEMATOLOGICA

Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma

(2009) Michele Cavo et al.   JOURNAL OF CLINICAL ONCOLOGY

Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

(2009) Andrew Spencer et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study

(2009) Ingemar Turesson et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

(2009) ZiYi Lim et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease

(2008) Robbert Spaapen et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Comparison of Twin and Autologous Transplants for Multiple Myeloma

(2008) Asad Bashey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

(2008) B. Bruno et al.   BLOOD

Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma

(2008) P. Moreau et al.   BLOOD

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

(2008) L. Rosinol et al.   BLOOD

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

(2008) M. Rotta et al.   BLOOD

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

(2008) Mauricio Pineda-Roman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy

(2008) W. Song et al.   CLINICAL CANCER RESEARCH

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

(2008) J. El-Cheikh et al.   HAEMATOLOGICA

Toward targeting B cell cancers with CD4+CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis

(2008) Robbert M. Spaapen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

(2008) G Schilling et al.   LEUKEMIA

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells

(2008) M C Minnema et al.   LEUKEMIA